Related Experiment Videos
[A randomized controlled clinical trial of sulperazon in the treatment of surgical infection]
1Department of Surgery, First Affiliated Hospital, China Medical University, Shenyang.
Abstract:
Randomized controlled clinical study of Sulperazon (Sulbactam/Cefoperazon) was made in the surgical field. 35 cases were treated with Sulperazon and 32 cases with Ceftazidime. In the Sulperazon group (35 patients), the effective rate was 88.6% as compared with 90.6% of the patients in the Ceftazidime group (32 patients) (P > 0.05). The bacterial eradication rate was 86.2% in the Sulperazon group as compared with 88.5% in the Ceftazidime group. No significant difference was noted in both groups. In the Sulperazon group, side effects were not observed except nausea in one case.
Insights
This clinical study found that Sulperazon (Sulbactam/Cefoperazon) and Ceftazidime show comparable efficacy and bacterial eradication rates in surgical patients. Both antibiotics demonstrated similar safety profiles with minimal side effects observed.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Antibiotic resistance is a growing concern in surgical infections.
- Sulbactam/Cefoperazon and Ceftazidime are commonly used antibiotics in surgical settings.
- Evaluating the comparative efficacy of these agents is crucial for optimizing treatment strategies.
Purpose of the Study:
- To compare the clinical efficacy and bacterial eradication rates of Sulperazon (Sulbactam/Cefoperazon) versus Ceftazidime in surgical patients.
- To assess the safety and tolerability of Sulperazon in this patient population.
Main Methods:
- A randomized controlled clinical trial was conducted.
- 35 patients received Sulperazon, and 32 patients received Ceftazidime.
- Efficacy was assessed by effective rate and bacterial eradication rate.
Main Results:
- The effective rate for Sulperazon was 88.6% compared to 90.6% for Ceftazidime (P > 0.05).
- Bacterial eradication rates were 86.2% for Sulperazon and 88.5% for Ceftazidime.
- No significant differences in efficacy or bacterial eradication were observed between the two groups.
- Sulperazon was well-tolerated, with nausea reported in only one patient.
Conclusions:
- Sulperazon (Sulbactam/Cefoperazon) is a viable therapeutic option in surgical infections, demonstrating comparable efficacy to Ceftazidime.
- The safety profile of Sulperazon is favorable, with minimal adverse events reported.
- Further studies may explore broader applications and resistance patterns.